Compare · INCY vs MEDP
INCY vs MEDP
Side-by-side comparison of Incyte Corp. (INCY) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCY and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $22.61B, about 1.3x MEDP ($17.21B).
- Over the past year, INCY is up 28.5% and MEDP is up 22.2% - INCY leads by 6.3 points.
- MEDP has been more active in the news (13 items in the past 4 weeks vs 11 for INCY).
- Both have 25 recent analyst ratings on file.
- Company
- Incyte Corp.
- Medpace Holdings Inc.
- Price
- $113.26+1.46%
- $628.86+1.97%
- Market cap
- $22.61B
- $17.21B
- 1M return
- -9.22%
- +1.99%
- 1Y return
- +28.46%
- +22.17%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 11
- 13
- Recent ratings
- 25
- 25
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest INCY
- Incyte to Report Third Quarter Financial Results
- Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
- SEC Form 4 filed by Incyte Corp.
- Director Baker Bros. Advisors Lp was granted 644 shares (SEC Form 4)
- Director Clancy Paul J was granted 203 shares, increasing direct ownership by 0.79% to 25,838 units (SEC Form 4)
- Director Harrigan Edmund was granted 206 shares, increasing direct ownership by 0.89% to 23,225 units (SEC Form 4)
- MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
- Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
- EVP, Chief Strategy Officer Gardner David H covered exercise/tax liability with 920 shares, decreasing direct ownership by 5% to 15,904 units (SEC Form 4) to satisfy withholding tax
- Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
Latest MEDP
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 4 filed by Medpace Holdings Inc.
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)
- Director Kraft Robert O. converted options into 32 shares, increasing direct ownership by 3% to 987 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.13% to 27,861 units (SEC Form 4)
- President & CEO Troendle August J. sold $30,320,929 worth of shares (48,667 units at $623.03), decreasing direct ownership by 13% to 338,225 units (SEC Form 4)
- UBS resumed coverage on Medpace with a new price target
- President & CEO Troendle August J. sold $1,589,941 worth of shares (2,564 units at $620.10), decreasing direct ownership by 0.66% to 386,892 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $27,403,895 worth of shares (43,916 units at $624.01), decreasing direct ownership by 10% to 389,456 units (SEC Form 4)